Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Burmeister

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Australasian Radiology|August 2, 2003
A prospective trial of short-fractionation radiotherapy for the palliation of liver metastasesS Bydder, N A Spry, D R H Christie, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 19, 2018
Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the OesophagusR Effeney, T Shaw, B H Burmeister, et al.
Head & Neck|November 15, 2011
Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapySandro V Porceddu, David I Pryor, Elizabeth Burmeister, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 1996
Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)J W Denham, B H Burmeister, D S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2010
T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02John H L Matthews, Bryan H Burmeister, Martin Borg, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 1995
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter studyB H Burmeister, J W Denham, M O'Brien, et al.
The British Journal of Surgery|February 5, 2004
Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapyW A Brown, J Thomas, D Gotley, et al.
Diseases of the Colon and Rectum|May 21, 2005
Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801)Samuel Y K Ngan, Richard Fisher, Bryan H Burmeister, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2010
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trialBryan H Burmeister, Janine M Thomas, Elizabeth A Burmeister, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|October 26, 2007
Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapyB M Smithers, M Cullinan, J M Thomas, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Australasian Radiology|August 2, 2003
A prospective trial of short-fractionation radiotherapy for the palliation of liver metastasesS Bydder, N A Spry, D R H Christie, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 19, 2018
Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the OesophagusR Effeney, T Shaw, B H Burmeister, et al.
Head & Neck|November 15, 2011
Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapySandro V Porceddu, David I Pryor, Elizabeth Burmeister, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 1996
Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)J W Denham, B H Burmeister, D S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2010
T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02John H L Matthews, Bryan H Burmeister, Martin Borg, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 1995
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter studyB H Burmeister, J W Denham, M O'Brien, et al.
The British Journal of Surgery|February 5, 2004
Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapyW A Brown, J Thomas, D Gotley, et al.
Diseases of the Colon and Rectum|May 21, 2005
Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801)Samuel Y K Ngan, Richard Fisher, Bryan H Burmeister, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2010
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trialBryan H Burmeister, Janine M Thomas, Elizabeth A Burmeister, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|October 26, 2007
Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapyB M Smithers, M Cullinan, J M Thomas, et al.
Pageof 8